Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Inavolisib in Participants With Hepatic Impairment
NCT07144111Phase 1Completed
- Sponsor
- Genentech
- Start
- Aug 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of inavolisib in breast cancer (3 cohorts), sponsored by Genentech. Primary endpoints: Maximum Observed Concentration of Inavolisib, Area Under Curve from Hour 0 to the Last Measurable Concentration of Inavolisib and 4 more. Started Aug 2025; status: completed.
02
Drugs
inavolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07144111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07144111.